MedPath
HSA Approval

APO-ALFUZOSIN PROLONGED RELEASE TABLET 10mg

SIN15512P

APO-ALFUZOSIN PROLONGED RELEASE TABLET 10mg

APO-ALFUZOSIN PROLONGED RELEASE TABLET 10mg

July 19, 2018

PHARMAFORTE SINGAPORE PTE LTD

PHARMAFORTE SINGAPORE PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantPHARMAFORTE SINGAPORE PTE LTD
Licence HolderPHARMAFORTE SINGAPORE PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, EXTENDED RELEASE

ORAL

Medical Information

G04CA01

alfuzosin

Manufacturer Information

PHARMAFORTE SINGAPORE PTE LTD

Apotex Inc (Signet)

Apotex Inc (Weston Road) (Primary and Secondary Packager)

Active Ingredients

Alfuzosin Hydrochloride

10mg

Alfuzosin

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

APO-ALFUZOSIN PROLONGED RELEASE TABLET 10mg - HSA Approval | MedPath